Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO1999002142 - NOUVELLE COMPOSITION

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

Claims

1. A pharmaceutical composition comprising an SSRI in quick-release form and a β-blocker in sustained-release form.

2. A pharmaceutical composition according to claim 1 which takes the form of a bi-layer tablet in which one layer contains the SSRI in a quick-release formulation and the other layer contains the β-blocker in a sustained-release formulation.

3. A pharmaceutical composition according to claim 1 which takes the form of a capsule which contains an admixture of a quick-release formulation of the SSRI and a sustained-release formulation of the β-blocker.

4. A pharmaceutical composition according to any one of claims 1 to 3 in which the β-blocker is in a sustained release form having a release profile in vitro in which the T50o/o is 1.73 hours ± 20%, the T90o/o is 8.45 hours ± 20% and the T100o/o is 14 hours ± 20%.

5. A pharmaceutical composition according to any one of claims 1 to 4 in which the SSRI is paroxetine or a pharmaceutically acceptable derivative thereof.

6. A pharmaceutical composition according to claim 5 in which the paroxetine is in the form of the hydrochloride.

7. A pharmaceutical composition according to any one of claims 1 to 6 in which the β-blocker is pindolol.

8. A pharmaceutical composition according to claim 7 in which the pindolol is present as the racemate.

9. A pharmaceutical composition according to claim 8 which contains 20mg of paroxetine hydrochloride and 7.5mg of pindolol as the racemate.

10. A pharmaceutical composition according to claim 7 in which the pindolol is present as an active isomer.

11. A method of treatment of alcoholism, anxiety, depression, obsessive compulsive disorder (OCD), panic disorder, chronic pain, obesity, senile dementia, migraine, bulimia, anorexia, social phobia, premenstrual syndrome (PMS), adolescent depression, trichotillomania, dysthymia, and substance abuse which comprises administering an effective or prophylactic amount of a pharmaceutical composition as defined in claim 1 according to any one of claims 1 to 10 to a sufferer in need thereof.

12. The use of a pharmaceutical composition as defined in claims 1 to 10 in the manufacture of a medicament for the treatment or prevention of alcoholism, anxiety, depression, obsessive compulsive disorder (OCD), panic disorder, chronic pain, obesity, senile dementia, migraine, bulimia, anorexia, social phobia, premenstrual syndrome (PMS), adolescent depression, trichotillomania, dysthymia, and substance abuse.

13. A pharmaceutical composition as defined in claims 1 to 10 for use in the treatment or prevention of alcoholism, anxiety, depression, obsessive compulsive disorder (OCD), panic disorder, chronic pain, obesity, senile dementia, migraine, bulimia, anorexia, social phobia, premenstrual syndrome (PMS), adolescent depression, trichotillomania, dysthymia, and substance abuse.